Buenos Aires, Argentina; Instituto Médico Especializado Alexander Fleming
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Cordoba, Argentina; Instituto Oncologico De Cordoba
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Santa Fe, Argentina; Isis Clinica Especializada
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Box Hill, Australia; Department Of Medical Oncology, Box Hill Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Coffs Harbour, Australia; Coffs Harbour Health Campus
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Newcastle, Australia; David Maddison Building
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Port Macquarie, Australia; Port Macquarie Base Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Brasschaat, Belgium; Az Klina
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Bruxelles, Belgium; Cliniques Universitaires Saint-Luc
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Charleroi, Belgium; Centre Hospitalier Notre Dame Et Reine Fabiola
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Edegem, Belgium; University Hospital Antwerp
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Gent, Belgium; Universitair Ziekenhuis Gent
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Montreal, Canada; Hopital Maisonneuve-Rosemont
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Montreal, Canada; Smbd Jewish General Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Santiago, Chile; Fundacion Arturo Lopez Perez
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Bordeaux, France; Hopital Saint Andre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Brest, France; Hopital Morvan
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Lyon, France; Hopital Hotel Dieu
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Marseille Cedex 09, France; Hopital Sainte Marguerite
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Nantes, France; Hotel Dieu
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Paris Cedex 10, France; Hopital Saint Louis
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Saint Etienne, France; Chu De Saint Etienne
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Wurzburg, Germany; Universitatsklinikum Wurzburg
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Gyula, Hungary; Pandy Kalman Megyei Korhaz
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Miskolc, Hungary; Semmelweis Korhaz Rendelointezet
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Szegedi, Hungary; Szgedi Tudomanyegyetern
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Haifa, Israel; Rambam Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Holon, Israel; Wolfson Medical Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Jerusalem, Israel; Hadassah Hebrew University Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Genova, Italy; Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Milano, Italy; Istituto Europeo Di Oncologia
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Napoli, Italy; Istituto Nazionale Tumori Fondazione Pascale
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Padova, Italy; Istituto Oncologico Veneto
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Siena, Italy; Azienda Ospedaleira Universitaria Senese S. Maria Alle Scott
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Eindhoven, Netherlands; Catharina Ziekenhuis
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Mb Amsterdam, Netherlands; Vu Medical Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Oslo, Norway; Department Of Clinical Cancer Research
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Gdansk, Poland; Wojewodzkie Centrum Onkologii
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Lodz, Poland; Regionalny Osrodek Onkolologiczy Wojewodzkii Szpital Specjal
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Lublin, Poland; Centrum Onkologii Ziemi Lubelskiej
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Poznan, Poland; Wielkopolskie Centrum Onkologii
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Wroclaw, Poland; Wojewodzki Szpital Specjalistyczny
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Coimbra, Portugal; Ipo De Coimbra Fg E.P.E.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Lisboa, Portugal; Instituto Portugues De Oncologia De Lisboa Fg E.P.E.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Porto, Portugal; Ipo Do Porto Fg E.P.E.
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Setubal, Portugal; Hospital De Sao Bernardo
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Barnaul, Russian Federation; Altai Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Moscow, Russian Federation; N. N. Blokhin Russian Cancer Research Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Murmansk, Russian Federation; Murmansk Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Ryazan, Russian Federation; Regional Clinical Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Samara, Russian Federation; Samara Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
St Petersburg, Russian Federation; City Clinical Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
St. Petersburg, Russian Federation; Leningrad Regional Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Stavropol, Russian Federation; Stavropol Regional Clinical Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Voronezh, Russian Federation; Voronezh Regional Clinical Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Johannesburg, South Africa; Sandton Oncology Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Panorama, South Africa; Gvi Oncology Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Port Elizabeth, South Africa; Eastern Cape Oncology Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Pretoria, South Africa; Wilgers Oncology Center
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Saxonwold, South Africa; Medical Oncology Center Of Rosebank
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Canarias, Spain; Hospital Univ. De Canarias
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Malaga, Spain; Hospital Universitario Virgen De La Victoria
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Valencia, Spain; Hospital General Universitario
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Zaragoza, Spain; Hospital Universitario Miguel Servet
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Cherkassy, Ukraine; Cherkassy Regional Oncology Dispensary
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Dnepropetrovsk, Ukraine; Dnepropetrovsk State Medical Academy
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Kiev, Ukraine; Institute Of Oncology Ams Of Ukraine
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Lviv, Ukraine; Lviv State Oncology Regional Treatment And Diagnostic Centre
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Uzhgorod, Ukraine; Uzhgorod National University
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
London, United Kingdom; The Royal Marsden Hospital
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Wirral, United Kingdom; Clatterbridge Centre For Oncology
Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
